January 11, 2023 Sequana Medical announces Extraordinary General Meeting of Shareholders on 10 February 2023 Regulated EN NL
November 15, 2022 Sequana Medical announces positive top-line results from SAHARA Ph. 2a study of DSR 1.0 in diuretic-resistant heart failure patients with persistent congestion and first patient dosed successfully with DSR 2.0 in YUKON Inside information, Regulated EN NL
November 8, 2022 Sequana Medical to present at Jefferies London Healthcare Conference Non-regulated EN NL
October 25, 2022 Sequana Medical announces positive top-line results from the North American pivotal alfapump® study (POSEIDON) Inside information, Regulated EN NL
October 21, 2022 Data from Roll-In Cohort of North American pivotal alfapump® study (POSEIDON) selected for poster presentation at AASLD The Liver Meeting® Non-regulated EN NL
September 8, 2022 Sequana Medical announces H1 2022 results and provides business update Inside information, Regulated EN NL
September 1, 2022 Sequana Medical Notice of 2022 Half Year Results and Business Update Non-regulated EN NL
July 20, 2022 Sequana Medical secures EUR 10 million loan facility with Kreos Capital Inside information, Regulated EN NL
July 19, 2022 Sequana Medical completes enrollment in Phase 2a SAHARA I DSR study, reports disease-modifying profile for Short Term DSR and provides business update Inside information, Regulated EN NL